CN101195016B - 一种治疗中风病的药物及其制备工艺 - Google Patents
一种治疗中风病的药物及其制备工艺 Download PDFInfo
- Publication number
- CN101195016B CN101195016B CN2006101051148A CN200610105114A CN101195016B CN 101195016 B CN101195016 B CN 101195016B CN 2006101051148 A CN2006101051148 A CN 2006101051148A CN 200610105114 A CN200610105114 A CN 200610105114A CN 101195016 B CN101195016 B CN 101195016B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- apoplexy
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 208000006011 Stroke Diseases 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 15
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 241000208340 Araliaceae Species 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 241000237903 Hirudo Species 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 241000305492 Gastrodia Species 0.000 claims description 4
- 241000219780 Pueraria Species 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241000407170 Curcuma Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 10
- 208000026435 phlegm Diseases 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000012567 medical material Substances 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000205574 Acorus calamus Species 0.000 abstract 1
- 235000006480 Acorus calamus Nutrition 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 208000034657 Convalescence Diseases 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000305491 Gastrodia elata Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 29
- 241000700159 Rattus Species 0.000 description 27
- 230000000302 ischemic effect Effects 0.000 description 13
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 10
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 9
- 229960000715 nimodipine Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 206010000117 Abnormal behaviour Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 244000164439 Curcuma angustifolia Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229940085393 aspirin 150 mg Drugs 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Abstract
Description
组别 | 剂量(g生药/kg) | 动物数(只) | 行为评分(分) |
缺血对照组 | 10 | 8.20±1.55 | |
蛭蛇通栓浸膏 | 6 | 10 | 5.60±1.78 |
蛭蛇通栓浸膏 | 3 | 10 | 6.35±1.70 |
蛭蛇通栓浸膏 | 1.5 | 9 | 7.17±1.15 |
尼莫地平 | 50mg/kg | 10 | 5.65±1.67 |
组别 | 剂量(g生药/kg) | 动物数(只) | 行为评分(分) |
缺血对照组 | 10 | 16.73±4.86 | |
蛭蛇通栓浸膏 | 6 | 10 | 9.49±3.44<sup>**</sup> |
蛭蛇通栓浸膏 | 3 | 10 | 10.97±4.22<sup>*</sup> |
组别 | 剂量(g生药/kg) | 动物数(只) | 行为评分(分) |
蛭蛇通栓浸膏 | 1.5 | 9 | 12.61±3.60 |
尼莫地平 | 50mg/kg | 10 | 10.45±3.63<sup>**</sup> |
组别 | 剂量(g生药/kg) | 动物数(只) | 梗塞组织重量/大脑半球重量(%) |
缺血对照组 | 10 | 15.53±5.47 | |
蛭蛇通栓浸膏 | 6 | 10 | 10.65±3.41<sup>*</sup> |
蛭蛇通栓浸膏 | 3 | 10 | 11.47±4.40 |
蛭蛇通栓浸膏 | 1.5 | 10 | 12.58±4.45 |
尼莫地平 | 50mg/kg | 10 | 9.57±2.48<sup>**</sup> |
组别 | 剂量(g生药/kg) | 动物数(只) | OT值(分) |
对照组 | 10 | 14.17±2.22 | |
蛭蛇通栓浸膏 | 6 | 10 | 19.65±4.26<sup>**</sup> |
蛭蛇通栓浸膏 | 3 | 10 | 18.04±3.07<sup>**</sup> |
蛭蛇通栓浸膏 | 1.5 | 10 | 16.02±1.99 |
阿司匹林 | 150mg/kg | 10 | 18.6±2.81<sup>**</sup> |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101051148A CN101195016B (zh) | 2006-12-05 | 2006-12-05 | 一种治疗中风病的药物及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101051148A CN101195016B (zh) | 2006-12-05 | 2006-12-05 | 一种治疗中风病的药物及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101195016A CN101195016A (zh) | 2008-06-11 |
CN101195016B true CN101195016B (zh) | 2010-06-23 |
Family
ID=39545762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101051148A Expired - Fee Related CN101195016B (zh) | 2006-12-05 | 2006-12-05 | 一种治疗中风病的药物及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101195016B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552811B (zh) * | 2012-01-27 | 2013-05-29 | 王政乾 | 一种治疗中风病的口服中药组合物 |
CN103028082B (zh) * | 2012-11-26 | 2014-03-12 | 安徽华佗国药股份有限公司 | 治疗脑血管疾病的中药及其制备方法 |
CN104398981A (zh) * | 2014-11-18 | 2015-03-11 | 黄永阳 | 偏瘫复原汤 |
CN104688862A (zh) * | 2015-03-13 | 2015-06-10 | 于振兰 | 气虚血瘀型中风治疗药物和配制方法以及检测方法 |
CN104958572B (zh) * | 2015-07-16 | 2017-05-17 | 中国中医科学院西苑医院 | 一种治疗缺血性中风及中风后抑郁的中药组合物及其制法 |
CN109010701A (zh) * | 2018-10-17 | 2018-12-18 | 北京太阳升高科医药研究股份有限公司 | 一种中药胶囊的制备工艺及中药胶囊 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1686510A (zh) * | 2005-04-14 | 2005-10-26 | 赵宏伟 | 一种防治脑中风的中成药 |
-
2006
- 2006-12-05 CN CN2006101051148A patent/CN101195016B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1686510A (zh) * | 2005-04-14 | 2005-10-26 | 赵宏伟 | 一种防治脑中风的中成药 |
Also Published As
Publication number | Publication date |
---|---|
CN101195016A (zh) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101195016B (zh) | 一种治疗中风病的药物及其制备工艺 | |
CN104873705A (zh) | 一种治疗冠心病心绞痛的药物组合物及其应用 | |
CN101152243B (zh) | 一种治疗中风病的中药组合物的制备工艺 | |
CN103341127A (zh) | 一种配合血液透析治疗尿毒症的中药及制备方法 | |
CN105497439A (zh) | 一种治疗妇产科术后低热症的药物组合物 | |
CN104922426A (zh) | 一种治疗妇产科术后低热症的药物组合物 | |
CN111643605A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN103191322A (zh) | 一种治疗重症急性胰腺炎的中药 | |
CN105641344A (zh) | 一种用于治疗便秘的药物制剂及其用途和制备方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN103638304A (zh) | 一种治疗肝阳上亢型偏头痛的中药制剂及其制备方法 | |
CN103263658A (zh) | 一种治疗周围性面瘫的中药制剂及其制备方法 | |
CN103028071A (zh) | 用于治疗腹泻型肠易激综合征的中药组合物及其制备方法 | |
CN103705733B (zh) | 一种治疗心律不齐的中药胶囊及其制备方法 | |
CN102293985A (zh) | 用于治疗冠心病的中药组合物及其制备方法 | |
CN1135997C (zh) | 治疗心脑血管病的药物 | |
CN101549140B (zh) | 治疗艾滋病的中药组合物及其制备方法 | |
CN104435685A (zh) | 一种治疗干眼症的药物及其制备方法 | |
CN104127737A (zh) | 用于防治痔疮术后并发症的药物组合物及其制备方法 | |
CN104257871B (zh) | 用于治疗湿热毒蕴型急性网状淋巴管炎的药物组合物及其制备方法 | |
CN105343688A (zh) | 一种治疗心肌梗塞的药物组合物及其应用 | |
CN104491557A (zh) | 一种治疗邪阻胃肠型有机磷农药中毒的药物及其制备方法 | |
CN101439150A (zh) | 一种治疗肠炎的中药组合物 | |
CN105125886A (zh) | 一种用于预防和治疗糖尿病及其并发症的中药组合物 | |
CN115364185A (zh) | 一种通降胃气治疗胃胀的中药片剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20150407 Granted publication date: 20100623 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
ASS | Succession or assignment of patent right |
Owner name: XI'AN CHINA RAILWAY INVESTMENT DEVELOPMENT CO., LT Effective date: 20150720 |
|
C41 | Transfer of patent application or patent right or utility model | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20150706 Granted publication date: 20100623 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150720 Address after: 712000 Xianyang city of Shaanxi province Jade Spring Road West of Nanjing Science and Technology Industrial Park Patentee after: Shaanxi Jianmin Pharmaceutical Co., Ltd. Patentee after: Xi'an China Railway Investment & Development Co., Ltd. Address before: Shaanxi province Xianyang City Qin road 712000 No. 6 Patentee before: Shaanxi Jianmin Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100623 Termination date: 20161205 |